Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
IBA Reports Full Year 2023 Results | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
By: GlobeNewswire - 21 Mar 2024 | Back to overview list |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GROUP REVENUES UP 18.7% WITH OTHER ACCELERATORS UP 51.1% REBIT POSITIVE FOR FY23 WITH OTHER ACCELERATORS REBIT ALMOST QUADRUPLING MEDIUM TERM GUIDANCE REITERATED Louvain-la-Neuve, Belgium, 21 March 2024 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its consolidated results for the 2023 financial year.
Olivier Legrain, Chief Executive Officer of IBA, commented: “A strong second half performance has ensured we have delivered positive REBIT at the full year, with Group revenues in line with expectations.” “Other Accelerators had a particularly strong year, with revenues growing more than 50% and a significant increase in REBIT driven by high order intake over the past few years and accelerated backlog conversion. Dosimetry performance was also strong, with growth in sales and REBIT, and the Services business continuing to perform well across the board. Meanwhile, Proton Therapy’s reduced performance reflects the significant investment into the future growth of the business alongside some delays in backlog conversion.” “Looking ahead, IBA remains focused on keeping its supply chain moving and accelerating backlog conversion. Alongside this, investment is important for the business and will be executed with an agile and targeted approach.” “As we continue to drive growth, I’m pleased to announce Henri de Romrée’s appointment as Deputy CEO, where he will focus on future opportunities and performance in the Other Accelerators business.” Financial summary
Business summary (including post-period end)
***ENDS*** IBA’s management team will host a hybrid event, including a conference call and webcast conducted in English, to present the full year results, followed by a Q&A session. The conference call will be held on Thursday, 21 March 2024 at 3pm CET / 2pm GMT / 10am ET / 7am PT as a Teams webinar and can be accessed online via this link. If you would like to join by phone only, please dial (Phone conference ID 204 708 166#): The presentation will be available on IBA’s investor relations website and on https://www.iba-worldwide.com/full-year-results-2023-press-release-and-conference-call shortly before the call. To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast. For participants who do not have the Teams application installed, please follow the process described in this link to access the conference. Financial calendar About IBA IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,000 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance. IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com For further information, please contact: Olivier Lechien For media and investor enquiries: 1 Proteus®ONE and Proteus®PLUS are brand names of Proteus 235
Attachment |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright 2024 GlobeNewswire | Back to overview list |